Cancer vaccines: should we be targeting patients with less aggressive disease?

Expert Rev Vaccines. 2012 Jun;11(6):721-31. doi: 10.1586/erv.12.39.


There is enthusiasm for using vaccines to stimulate the immune system to treat cancer. In this article, the authors review the evolution of vaccines evaluated in clinical trials, starting with Phase III trials in metastatic disease and progressing to trials in the adjuvant setting. Data from these trials suggest that cancer vaccines may be more effective in patients with lower volume disease, and data from the E75 peptide vaccine trials suggest that vaccines may be most effective in less aggressive disease.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Cancer Vaccines / administration & dosage*
  • Cancer Vaccines / immunology*
  • Clinical Trials as Topic
  • Humans
  • Neoplasms / immunology
  • Neoplasms / pathology*
  • Neoplasms / therapy*
  • Vaccination / methods*


  • Cancer Vaccines